"Today there are a total of 18 special lectures and two academic reports, which is a little less than tomorrow. It will end at 6 pm, and the lunch break will be about two hours."
"If there is a surgical demonstration in the special lecture, it will probably take too long and I may not be able to finish it even after lunch."
"Don't you have confidence in the surgeons here in the capital?"
"The operation time of hepatobiliary surgery is relatively long. If they start the operation earlier in the hospital, we won't be able to see it in time."
"Would you like to watch a demonstration surgery?"
"See. But it depends on who does the surgery and what kind of surgery it is."
Listening to these people's discussions, the situation was similar to the estimates made by their department, Xie Wanying thought.
"I know Professor Hao from Juyang Hospital." A colleague suddenly pointed out one of the lectures and said.
"This is a lecture that starts at 8:30. The topic is intrabiliary radiotherapy for PTCD."
...
...
The insertion of a bile duct stent after percutaneous transhepatic biliary drainage is mainly used for patients with pancreatic head cancer, bile duct cancer, ampullary cancer and other cancers that are difficult to detect in the early stages and are already in the middle to late stages once discovered. These patients also have another characteristic: high collarbone, poor cardiopulmonary function, and inability to tolerate radical surgery, so they can only receive palliative treatment.
This treatment method only relieves malignant bile duct obstruction caused by late-stage cancer. However, the stent itself cannot inhibit tumor growth and will continue to grow along the drainage stent, causing obstruction again. In order to keep the drainage unobstructed, doctors have come up with many ways to avoid stent obstruction. One of them is the transcatheter 192lr wire close-range radiotherapy in the bile duct, which was first invented abroad in the 1980s.
192LR is the radioactive source iridium-192, and Ir is the symbol of the nuclide. It is a relatively mature technology used in various close-range radiotherapy in the human cavity. The first cancer that was widely used in the human body was cervical cancer, and then it was expanded to bile duct cancer, tongue cancer, etc. In the application of cervical cancer, it can be used as one of the treatment methods to shrink the tumor before surgery. However, in hepatobiliary surgery, it is only used as a palliative treatment in the late stage.
Palliative treatment is equivalent to a treatment measure that basically has no long-term hope for the patient's survival. Data from various academic papers show that the survival of patients with malignant biliary obstruction is generally only two months. If PTCD plus 192lr brachytherapy is used, the patient's survival can be extended to more than two years, depending on the size of the tumor. For patients with advanced cancer, living one more day is meaningful.
The doctors who had discussed the issue earlier decided to go to Professor Hao's lecture on PTCD intraductal radiotherapy. Xie Wanying followed him, mainly because she saw that there were quite a lot of people attending the lecture. It was clear that everyone had the same inclination.
The hotel's reserved multimedia conference rooms were basically renovated from small halls or rooms. They were not very large, and some only had about a hundred seats. When I entered the conference room, I found that the front row seats were full. Xie Wanying found a seat in the back row and sat down.
Just as she was sitting next to the chair, two people came in from the door. One of them noticed her and turned to walk towards her.
"Is it Xie Wanying?"
Hearing someone calling her name, Xie Wanying looked up. The male doctor standing in front of her was tall, with a briefcase on his shoulder, and his face seemed familiar to her.
"Don't you remember me? But I remember you very well. You and the other two came to the emergency room of Xuanwu Hospital that night. After Doctor Cao took you back, what happened to you?"
Continue read on readnovelmtl.com
